CASSIOPEIA — Daratumumab Plus Bortezomib-Thalidomide-Dexamethasone (D-VTd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (CASSIOPEIA)

Phase 3 · 2019 · Multiple Myeloma

Design

Randomized trial of daratumumab plus VTd vs VTd as induction and consolidation around autologous stem-cell transplant (Part 1).

Population

Transplant-eligible newly diagnosed multiple myeloma.

Primary Endpoint

stringent complete response (sCR) at day 100 post-transplant

Key Result

sCR 29% vs 20% (P=0.0010); progression-free survival favored D-VTd (HR 0.47) with deeper MRD-negative responses.

Guideline Impact

NCCN-listed daratumumab-based induction for transplant-eligible newly diagnosed multiple myeloma